cemiplimab,fianlimab
regeneron,sanofi
['melanoma', 'fianlimab', 'cemiplimab']
 s dr. eugenia girda &amp; colleagues present a phase 1 study of fianlimab (anti-lag-3) in combination with cemiplimab (anti-pd-1) in patients with advanced #melanoma: poor-prognosis subgroup analysis. at #asco23 (link below) 
Rutgers Cancer Institute of New Jersey is the state’s only NCI-designated Comprehensive Cancer Center and a leader in patient care and cancer research.